Scholarlink

Background <p>Patients with early recurrence of hormone receptor (HR)-positive, HER2-negative (HR+/HER2−) breast cancer have a poor prognosis. We aimed to identify clinical and pathological risk factors for recurrence within three years after surgery of HR+/HER2− breast cancer.</p> Methods <p>We retrospectively reviewed clinical data of patients with stage II–III HR+/HER2− breast cancer who received adjuvant endocrine therapy from January 1, 2012 to January 1, 2017 at five institutions. Using univariable and multivariable analyses, we determined risk factors for invasive disease-free survival (IDFS). A nomogram was generated using variables from the multivariable analysis to predict 3-year IDFS rate.</p> Results <p>A total of 2732 patients were analyzed, with a median follow-up of 7.1&#xa0;years. The 3-year IDFS rate was 92.1%. Multivariable analysis for IDFS revealed significant risk factors: age (40–69 vs. 20–39&#xa0;years: HR 0.69, <i>p</i> = 0.011), nuclear grade (Grade 2 vs. Grade 1: HR 1.66, <i>p</i> &lt; 0.001; Grade 3 vs. Grade 1: HR 1.64, <i>p</i> &lt; 0.001), vascular invasion (Yes vs. No: HR 1.36, <i>p</i> = 0.027), pathological invasive tumor size (2–5&#xa0;cm vs. &lt; 2&#xa0;cm: HR 1.75, <i>p</i> &lt; 0.001; ≥ 5&#xa0;cm vs. &lt; 2&#xa0;cm: HR 2.07, <i>p</i> &lt; 0.001), number of positive lymph nodes (≥ 4 vs.0: HR 1.70, <i>p</i> &lt; 0.001), and neoadjuvant chemotherapy (NAC) (Yes vs. No: HR 2.41, <i>p</i> &lt; 0.001). The nomogram’s concordance index was 0.68.</p> Conclusion <p>Younger age, nuclear grade, vascular invasion, tumor size and number of lymph node metastases were identified as independent risk factors for early recurrence. Patients whose physicians chose NAC had worse survival than those who did not.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Risk factors for early recurrence in patients with hormone receptor-positive, HER2-negative breast cancer: a retrospective cohort study in Japan (WJOG15721B)

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年4月10日

查看全文
  • Rurina Watanuki,
  • Hitomi Sakai,
  • Yuri Takehara,
  • Atsushi Yoshida,
  • Naoki Hayashi,
  • Yukinori Ozaki,
  • Akemi Kataoka,
  • Natsue Uehiro,
  • Hidenori Kamio,
  • Mai Onishi,
  • Atsushi Fushimi,
  • Takashi Ikeno,
  • Masashi Wakabayashi,
  • Mayumi Iida,
  • Tsutomu Kawaguchi,
  • Toshimi Takano

摘要

Background

Patients with early recurrence of hormone receptor (HR)-positive, HER2-negative (HR+/HER2−) breast cancer have a poor prognosis. We aimed to identify clinical and pathological risk factors for recurrence within three years after surgery of HR+/HER2− breast cancer.

Methods

We retrospectively reviewed clinical data of patients with stage II–III HR+/HER2− breast cancer who received adjuvant endocrine therapy from January 1, 2012 to January 1, 2017 at five institutions. Using univariable and multivariable analyses, we determined risk factors for invasive disease-free survival (IDFS). A nomogram was generated using variables from the multivariable analysis to predict 3-year IDFS rate.

Results

A total of 2732 patients were analyzed, with a median follow-up of 7.1 years. The 3-year IDFS rate was 92.1%. Multivariable analysis for IDFS revealed significant risk factors: age (40–69 vs. 20–39 years: HR 0.69, p = 0.011), nuclear grade (Grade 2 vs. Grade 1: HR 1.66, p < 0.001; Grade 3 vs. Grade 1: HR 1.64, p < 0.001), vascular invasion (Yes vs. No: HR 1.36, p = 0.027), pathological invasive tumor size (2–5 cm vs. < 2 cm: HR 1.75, p < 0.001; ≥ 5 cm vs. < 2 cm: HR 2.07, p < 0.001), number of positive lymph nodes (≥ 4 vs.0: HR 1.70, p < 0.001), and neoadjuvant chemotherapy (NAC) (Yes vs. No: HR 2.41, p < 0.001). The nomogram’s concordance index was 0.68.

Conclusion

Younger age, nuclear grade, vascular invasion, tumor size and number of lymph node metastases were identified as independent risk factors for early recurrence. Patients whose physicians chose NAC had worse survival than those who did not.